問卷

TPIDB > Search Result

Search Result

篩選

List

65Cases

2025-03-01 - 2028-04-30

Phase I

Active
An Open Label, Rollover Platform Study for Continued Study Treatment and Ongoing Safety Monitoring
  • Condition/Disease

    Leukemia, Myeloid, Acute

  • Test Drug

    皮下注射劑 膠囊劑

Participate Sites
4Sites

Recruiting4Sites

2024-09-15 - 2029-12-31

Phase II

Active
  • Condition/Disease

  • Test Drug

Participate Sites
5Sites

Recruiting5Sites

2024-06-01 - 2029-12-31

Phase III

Active
  • Condition/Disease

  • Test Drug

Participate Sites
8Sites

Recruiting8Sites

2024-09-01 - 2031-12-31

Phase III

Active
  • Condition/Disease

  • Test Drug

Participate Sites
9Sites

Recruiting9Sites

2025-11-07 - 2029-09-25

Phase III

Not yet recruiting
  • Condition/Disease

  • Test Drug

Participate Sites
8Sites

Recruiting8Sites

2023-11-01 - 2027-12-31

Phase II

Active
A Phase II, Open-label, Multi-centre Study to Evaluate Safety, Tolerability, Efficacy, PK, and Immunogenicity of AZD0901 as Monotherapy and in Combination with Anti-cancer Agents in Participants with Advanced Solid Tumours Expressing Claudin 18.2.
  • Condition/Disease

    Gastric Cancer Gastroesophageal Junction Cancer Pancreatic Adenocarcinoma

  • Test Drug

    AZD0901

Participate Sites
5Sites

Recruiting4Sites

2025-06-01 - 2027-09-30

Phase III

Active
A Phase 3, Open-Label, Randomized Study of BGB-16673 Compared to Investigator's Choice in Patients With Relapsed/Refractory Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma Previously Exposed to Covalent BTK Inhibitors
  • Condition/Disease

    Chronic Lymphocytic Leukemia 、Small Lymphocytic Lymphoma

  • Test Drug

    錠劑

Participate Sites
5Sites

Recruiting5Sites

2023-07-01 - 2026-01-31

Phase II

Active
A Randomized, Phase 2, Open-Label, Multi-Arm Study of Tislelizumab in Combination With Investigational Agents as First-Line Treatment in Patients With Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma
  • Condition/Disease

    Head and Neck Squamous Cell Carcinoma、 Head and Neck Cancer

  • Test Drug

    BGB-A317 (Tislelizumab); BGB-A425; LBL-007

Participate Sites
4Sites

Not yet recruiting2Sites

Recruiting2Sites